Medicenna Therapeutics (OTCMKTS:MDNAF – Get Free Report) issued its earnings results on Thursday. The company reported $999.00 EPS for the quarter, topping the consensus estimate of ($0.05) by $999.05, reports.
Medicenna Therapeutics Trading Down 0.6%
MDNAF stock opened at $0.29 on Friday. Medicenna Therapeutics has a 1-year low of $0.25 and a 1-year high of $1.43. The company’s fifty day simple moving average is $0.36. The company has a market capitalization of $26.67 million, a price-to-earnings ratio of -1.81 and a beta of 1.71.
Medicenna Therapeutics Company Profile
Medicenna Therapeutics Corp. is a clinical-stage biopharmaceutical company focused on developing next-generation cytokine-based immunotherapies for cancer and central nervous system disorders. The company applies protein-engineering approaches to create engineered cytokine therapeutics designed to enhance anti-tumor activity while reducing systemic toxicity, aiming to broaden the therapeutic window for immunomodulatory agents.
Medicenna’s pipeline includes proprietary candidates such as MDNA55, an engineered interleukin-4 (IL-4) receptor-targeted fusion protein developed for intratumoral treatment of recurrent glioblastoma and other brain tumors, and MDNA11, a long-acting engineered interleukin-2 (IL-2) “superkine” intended to stimulate anti-tumor immune responses in solid tumors with an improved safety profile.
Recommended Stories
- Five stocks we like better than Medicenna Therapeutics
- MarketBeat Week in Review – 06/22 – 06/26
- Rocket Lab’s NASA Win Tests Key Support After Sharp Pullback
- AST SpaceMobile Just Nailed a Major Launch—So Why Is the Stock Crashing?
- Palantir’s Valuation Problem Just Met 2 New Growth Catalysts
Receive News & Ratings for Medicenna Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medicenna Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
